Biohaven (NYSE: BHVN) insider transactions
In the twelve months to 10 November 2026, executives and directors of Biohaven reported 0 open-market sales and 5 open-market purchases of 4,416,999 shares ($33.1m), by 4 people, according to the Form 4 filings they submitted to the SEC.
Latest transactions
| Date | Insider | Role | Transaction | Shares | Price | Held after | Filing |
|---|---|---|---|---|---|---|---|
| 17 March 2026 | Mehta Kishan | Director | Gift | −17,342 | — | 5,320 | Form 4 |
| 17 March 2026 | Mehta Kishan | Director | Gift | +17,342 | — | 17,342 | Form 4 |
| 5 January 2026 | Gentile Kimberly | SVP, Clinical Operations | Option exercise | +3,750 | — | 101,513 | Form 4 |
| 5 January 2026 | Gentile Kimberly | SVP, Clinical Operations | Shares withheld for tax | −1,956 | $9.93 | 99,557 | Form 4 |
| 5 January 2026 | Coric Vlad | Chief Executive Officer | Option exercise | +14,250 | — | 1,811,398 | Form 4 |
| 5 January 2026 | Coric Vlad | Chief Executive Officer | Shares withheld for tax | −7,430 | $9.93 | 1,803,968 | Form 4 |
| 5 January 2026 | Car Bruce | Chief Scientific Officer | Option exercise | +4,750 | — | 10,096 | Form 4 |
| 5 January 2026 | Car Bruce | Chief Scientific Officer | Shares withheld for tax | −2,381 | $9.93 | 7,715 | Form 4 |
| 5 January 2026 | Clark George C. | VP, Chief Accounting Officer | Option exercise | +2,500 | — | 68,095 | Form 4 |
| 5 January 2026 | Clark George C. | VP, Chief Accounting Officer | Shares withheld for tax | −1,117 | $9.93 | 66,978 | Form 4 |
| 5 January 2026 | Buten Matthew | Chief Financial Officer | Option exercise | +4,250 | — | 198,246 | Form 4 |
| 5 January 2026 | Buten Matthew | Chief Financial Officer | Shares withheld for tax | −2,594 | $9.93 | 195,652 | Form 4 |
| 17 November 2025 | Clark George C. | VP, Chief Accounting Officer | Open-market purchase | +17,000 | $8.52 | 20,000 | Form 4 |
| 13 November 2025 | Childs John W | Director | Open-market purchase | +3,333,333 | $7.50 | 5,653,904 | Form 4 |
| 13 November 2025 | Coric Vlad | Chief Executive Officer | Open-market purchase | +333,333 | $7.50 | 1,195,275 | Form 4 |
| 13 November 2025 | Coric Vlad | Chief Executive Officer | Open-market purchase | +333,333 | $7.50 | 740,546 | Form 4 |
| 13 November 2025 | Bailey Gregory | Director | Open-market purchase | +400,000 | $7.50 | 2,020,071 | Form 4 |
| 4 March 2025 | Childs John W | Director | Open-market purchase | +25,000 | $30.39 | 2,320,571 | Form 4 |
| 4 March 2025 | Childs John W | Director | Open-market purchase | +3,400 | $30.73 | 24,452 | Form 4 |
| 4 March 2025 | Childs John W | Director | Open-market purchase | +3,400 | $30.73 | 76,570 | Form 4 |
Names appear as in the filing, surname first. A dash in the price column means the filing reports none, as in grants and gifts.
How to read the table
Only open-market purchases and sales are trades the insider chose to make at the market price, and they are the ones counted in the summary above. Grants, option exercises and shares withheld for tax come from pay plans. A sale marked as a 10b5-1 plan was scheduled in advance under a written plan.
Where each row comes from
From the Form 4 that each executive, director or large shareholder must file with the SEC within two business days of a transaction, read up to 10 November 2026. Each row links to its filing on EDGAR. Only transactions in shares are listed, not derivatives, and amended filings are left out. The accounts of the company are on the Biohaven page; the method, in data sources.
Information prepared from the Form 4 filings submitted to the SEC, for information purposes only. It is not financial advice or a recommendation to buy or sell. Updated on 12 November 2026.